Abstract

The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BRCA1/2 genes, involves the need to optimise the guidelines for BRCA testing. The AIOM-SIGU-SIBIOC-SIAPEC-IAP Italian Scientific Societies, in this position paper, recommend the implementation of BRCA testing with 2 main objectives: the first is the identification of ovarian cancer patients with higher probability of benefit from specific anticancer treatments (test for response to therapy); the second goal, through BRCA testing in the family members of ovarian cancer patients, is the identification of carriers of pathogenic variant, who have inheredited predisposition to cancer development (test for cancer risk). These individuals with increased risk of cancer, should be encouraged to participate in dedicated high-risk surveillance clinics and specific risk-reducing measures (primary and/or secondary prevention programs). © 2019 The Authors
Original languageEnglish
Pages (from-to)67-72
Number of pages6
JournalCrit. Rev. Oncol. Hematol.
Volume140
DOIs
Publication statusPublished - 2019

Keywords

  • BRCA1
  • BRCA2
  • Genetic testing
  • Germline mutations
  • Ovarian cancer
  • PARP inhibitors
  • Somatic mutations
  • BRCA1 protein
  • BRCA2 protein
  • doxorubicin
  • nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor
  • niraparib
  • olaparib
  • rucaparib
  • trabectedin
  • cancer patient
  • cancer prognosis
  • cancer risk
  • cancer therapy
  • genetic analysis
  • genetic counseling
  • genetic predisposition
  • genetic variability
  • germline mutation
  • health care availability
  • heterozygote
  • high risk population
  • human
  • informed consent
  • medical society
  • mutational analysis
  • ovary cancer
  • ovary carcinoma
  • patient selection
  • peritoneum cancer
  • primary prevention
  • relative
  • Review
  • risk reduction
  • secondary prevention
  • sequence analysis
  • somatic mutation
  • treatment response
  • uterine tube carcinoma
  • biochemistry
  • female
  • genetic screening
  • genetics
  • Italy
  • oncology
  • ovary tumor
  • practice guideline
  • Biochemistry
  • BRCA1 Protein
  • BRCA2 Protein
  • Female
  • Genetic Testing
  • Genetics
  • Germ-Line Mutation
  • Humans
  • Medical Oncology
  • Ovarian Neoplasms
  • Societies, Medical

Fingerprint Dive into the research topics of 'Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives: Critical Reviews in Oncology/Hematology'. Together they form a unique fingerprint.

Cite this